Literature DB >> 25255089

Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Aran F Labrijn1, Joyce I Meesters1, Patrick Priem1, Rob N de Jong1, Ewald T J van den Bremer1, Muriel D van Kampen1, Arnout F Gerritsen1, Janine Schuurman1, Paul W H I Parren1.   

Abstract

The generation of bispecific antibodies (bsAbs) with natural IgG architecture in a practical and efficient manner has been a longstanding challenge. Here we describe controlled Fab-arm exchange (cFAE), which is an easy-to-use method to generate bispecific IgG1 (bsIgG1). The protocol involves the following: (i) separate expression of two parental IgG1s containing single matching point mutations in the CH3 domain; (ii) mixing of parental IgG1s under permissive redox conditions in vitro to enable recombination of half-molecules; (iii) removal of the reductant to allow reoxidation of interchain disulfide bonds; and (iv) analysis of exchange efficiency and final product using chromatography-based or mass spectrometry (MS)-based methods. The protocol generates bsAbs with regular IgG architecture, characteristics and quality attributes both at bench scale (micrograms to milligrams) and at a mini-bioreactor scale (milligrams to grams) that is designed to model large-scale manufacturing (kilograms). Starting from good-quality purified proteins, exchange efficiencies of ≥95% can routinely be obtained within 2-3 d (including quality control).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25255089     DOI: 10.1038/nprot.2014.169

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  29 in total

Review 1.  Antibody production.

Authors:  John R Birch; Andrew J Racher
Journal:  Adv Drug Deliv Rev       Date:  2006-05-22       Impact factor: 15.470

Review 2.  Bispecific antibodies for cancer therapy.

Authors:  Patrick Chames; Daniel Baty
Journal:  Curr Opin Drug Discov Devel       Date:  2009-03

3.  A simple, robust and highly efficient transient expression system for producing antibodies.

Authors:  Tom Vink; Maroeska Oudshoorn-Dickmann; Marcel Roza; Jelte-Jan Reitsma; Rob N de Jong
Journal:  Methods       Date:  2013-07-17       Impact factor: 3.608

4.  Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).

Authors:  Hui Zhao; Olivier Graf; Nebojsa Milovic; Xiaosong Luan; Markus Bluemel; Markus Smolny; Kurt Forrer
Journal:  J Pharm Sci       Date:  2010-05       Impact factor: 3.534

5.  Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites.

Authors:  J Schuurman; R Van Ree; G J Perdok; H R Van Doorn; K Y Tan; R C Aalberse
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

6.  SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.

Authors:  Jonathan H Davis; Christel Aperlo; Yue Li; Emmi Kurosawa; Yan Lan; Kin-Ming Lo; James S Huston
Journal:  Protein Eng Des Sel       Date:  2010-02-04       Impact factor: 1.650

7.  An efficient route to human bispecific IgG.

Authors:  A M Merchant; Z Zhu; J Q Yuan; A Goddard; C W Adams; L G Presta; P Carter
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

8.  Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.

Authors:  Aran F Labrijn; Theo Rispens; Joyce Meesters; Rebecca J Rose; Tamara H den Bleker; Stefan Loverix; Ewald T J van den Bremer; Joost Neijssen; Tom Vink; Ignace Lasters; Rob C Aalberse; Albert J R Heck; Jan G J van de Winkel; Janine Schuurman; Paul W H I Parren
Journal:  J Immunol       Date:  2011-08-12       Impact factor: 5.422

9.  Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

Authors:  Michael J Gramer; Ewald T J van den Bremer; Muriel D van Kampen; Amitava Kundu; Peter Kopfmann; Eric Etter; David Stinehelfer; Justin Long; Tom Lannom; Esther H Noordergraaf; Jolanda Gerritsen; Aran F Labrijn; Janine Schuurman; Patrick H C van Berkel; Paul W H I Parren
Journal:  MAbs       Date:  2013-08-22       Impact factor: 5.857

10.  Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity.

Authors:  Whitney Shatz; Shan Chung; Bing Li; Brett Marshall; Max Tejada; Wilson Phung; Wendy Sandoval; Robert F Kelley; Justin M Scheer
Journal:  MAbs       Date:  2013-08-29       Impact factor: 5.857

View more
  37 in total

1.  A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.

Authors:  Sayed Shahabuddin Hoseini; Hongfen Guo; Zhihao Wu; Miho Nakajima Hatano; Nai-Kong V Cheung
Journal:  Blood Adv       Date:  2018-06-12

2.  Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.

Authors:  Brian H Santich; Jeong A Park; Hoa Tran; Hong-Fen Guo; Morgan Huse; Nai-Kong V Cheung
Journal:  Sci Transl Med       Date:  2020-03-11       Impact factor: 17.956

3.  Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.

Authors:  Deepak Mittal; Dipti Vijayan; Joost Neijssen; Joost Kreijtz; Maurice M J M Habraken; Hans Van Eenennaam; Andrea Van Elsas; Mark J Smyth
Journal:  Oncoimmunology       Date:  2019-08-26       Impact factor: 8.110

Review 4.  The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.

Authors:  Jonathan T Sockolosky; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2015-02-19       Impact factor: 15.470

5.  Diffusion of Soluble Aggregates of THIOMABs and Bispecific Antibodies in Serum.

Authors:  Dennis R Goulet; Adam Zwolak; Mark L Chiu; Abhinav Nath; William M Atkins
Journal:  Biochemistry       Date:  2017-04-14       Impact factor: 3.162

Review 6.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

Review 7.  Bispecific antibodies and their applications.

Authors:  Gaowei Fan; Zujian Wang; Mingju Hao; Jinming Li
Journal:  J Hematol Oncol       Date:  2015-12-21       Impact factor: 17.388

8.  A detergent-based procedure for the preparation of IgG-like bispecific antibodies in high yield.

Authors:  Jyoti Gupta; Mehboob Hoque; Masihuz Zaman; Rizwan Hasan Khan; M Saleemuddin
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

9.  Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.

Authors:  Katharine D Grugan; Keri Dorn; Stephen W Jarantow; Barbara S Bushey; Jose R Pardinas; Sylvie Laquerre; Sheri L Moores; Mark L Chiu
Journal:  MAbs       Date:  2016-10-27       Impact factor: 5.857

Review 10.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.